FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014336844> ?p ?o ?g. }

• W2014336844 abstract "EGFR is frequently overexpressed in colon cancer. We characterized HT-29 and Caco-2, human colon cancer cell lines, untreated and treated with cetuximab or gefitinib alone and in combination with EGF.Cell growth was determined using a variation on the MTT assay. Cell-cycle analysis was conducted by flow cytometry. Immunohistochemistry was performed to evaluate EGFR expression and scanning electron microscopy (SEM) evidenced the ultrastructural morphology. Gene expression profiling was performed using hybridization of the microarray Ocimum Pan Human 40 K array A.Caco-2 and HT-29 were respectively 66.25 and 59.24 % in G0/G1. They maintained this level of cell cycle distribution after treatment, suggesting a predominantly differentiated state. Treatment of Caco-2 with EGF or the two EGFR inhibitors produced a significant reduction in their viability. SEM clearly showed morphological cellular transformations in the direction of cellular death in both cell lines treated with EGFR inhibitors. HT-29 and Caco-2 displayed an important reduction of the microvilli (which also lose their erect position in Caco-2), possibly invalidating microvilli absorption function. HT-29 treated with cetuximab lost their boundary contacts and showed filipodi; when treated with gefitinib, they showed some vesicles: generally membrane reshaping is evident. Both cell lines showed a similar behavior in terms of on/off switched genes upon treatment with cetuximab. The gefitinib global gene expression pattern was different for the 2 cell lines; gefitinib treatment induced more changes, but directly correlated with EGF treatment. In cetuximab or gefitinib plus EGF treatments there was possible summation of the morphological effects: cells seemed more weakly affected by the transformation towards apoptosis. The genes appeared to be less stimulated than for single drug cases.This is the first study to have systematically investigated the effect of cetuximab or gefitinib, alone and in combination with EGF, on human colon cancer cell lines. The EGFR inhibitors have a weaker effect in the presence of EGF that binds EGFR. Cetuximab treatment showed an expression pattern that inversely correlates with EGF treatment. We found interesting cyto-morphological features closely relating to gene expression profile. Both drugs have an effect on differentiation towards cellular death." @default.
• W2014336844 created "2016-06-24" @default.
• W2014336844 creator A5011065716 @default.
• W2014336844 creator A5017321881 @default.
• W2014336844 creator A5021856385 @default.
• W2014336844 creator A5026341152 @default.
• W2014336844 creator A5028267842 @default.
• W2014336844 creator A5028401119 @default.
• W2014336844 creator A5033144041 @default.
• W2014336844 creator A5040089756 @default.
• W2014336844 creator A5044261805 @default.
• W2014336844 creator A5044540514 @default.
• W2014336844 creator A5050961286 @default.
• W2014336844 creator A5056573599 @default.
• W2014336844 creator A5061366151 @default.
• W2014336844 creator A5067996122 @default.
• W2014336844 creator A5069842779 @default.
• W2014336844 creator A5076324164 @default.
• W2014336844 creator A5079246846 @default.
• W2014336844 creator A5089179081 @default.
• W2014336844 creator A5091357780 @default.
• W2014336844 date "2008-08-08" @default.
• W2014336844 modified "2023-10-15" @default.
• W2014336844 title "Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines" @default.
• W2014336844 cites W1546952499 @default.
• W2014336844 cites W1554880727 @default.
• W2014336844 cites W1912159405 @default.
• W2014336844 cites W1964321121 @default.
• W2014336844 cites W1968885065 @default.
• W2014336844 cites W1976231646 @default.
• W2014336844 cites W1978068596 @default.
• W2014336844 cites W1982637165 @default.
• W2014336844 cites W2012629036 @default.
• W2014336844 cites W2012906994 @default.
• W2014336844 cites W2020359797 @default.
• W2014336844 cites W2023660230 @default.
• W2014336844 cites W2029066006 @default.
• W2014336844 cites W2031844898 @default.
• W2014336844 cites W2033488181 @default.
• W2014336844 cites W2034269086 @default.
• W2014336844 cites W2039633811 @default.
• W2014336844 cites W2042520293 @default.
• W2014336844 cites W2051516139 @default.
• W2014336844 cites W2052753532 @default.
• W2014336844 cites W2058153177 @default.
• W2014336844 cites W2062821569 @default.
• W2014336844 cites W2065607376 @default.
• W2014336844 cites W2065969919 @default.
• W2014336844 cites W2066719256 @default.
• W2014336844 cites W2068125497 @default.
• W2014336844 cites W2070803253 @default.
• W2014336844 cites W2072652962 @default.
• W2014336844 cites W2076794242 @default.
• W2014336844 cites W2081098333 @default.
• W2014336844 cites W2081589784 @default.
• W2014336844 cites W2090328173 @default.
• W2014336844 cites W2096287391 @default.
• W2014336844 cites W2103384680 @default.
• W2014336844 cites W2106448082 @default.
• W2014336844 cites W2109044536 @default.
• W2014336844 cites W2114918609 @default.
• W2014336844 cites W2118069309 @default.
• W2014336844 cites W2122735301 @default.
• W2014336844 cites W2128085074 @default.
• W2014336844 cites W2129432386 @default.
• W2014336844 cites W2129579482 @default.
• W2014336844 cites W2130410032 @default.
• W2014336844 cites W2132392721 @default.
• W2014336844 cites W2135230352 @default.
• W2014336844 cites W2136526151 @default.
• W2014336844 cites W2138580634 @default.
• W2014336844 cites W2139195277 @default.
• W2014336844 cites W2140106545 @default.
• W2014336844 cites W2141097619 @default.
• W2014336844 cites W2142736780 @default.
• W2014336844 cites W2153534791 @default.
• W2014336844 cites W2161541244 @default.
• W2014336844 cites W2165674132 @default.
• W2014336844 cites W2167097542 @default.
• W2014336844 cites W2169332099 @default.
• W2014336844 cites W2188010225 @default.
• W2014336844 cites W2189451194 @default.
• W2014336844 cites W4244120980 @default.
• W2014336844 doi "https://doi.org/10.1186/1471-2407-8-227" @default.
• W2014336844 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2528013" @default.
• W2014336844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18691415" @default.
• W2014336844 hasPublicationYear "2008" @default.
• W2014336844 type Work @default.
• W2014336844 sameAs 2014336844 @default.
• W2014336844 citedByCount "25" @default.
• W2014336844 countsByYear W20143368442012 @default.
• W2014336844 countsByYear W20143368442013 @default.
• W2014336844 countsByYear W20143368442014 @default.
• W2014336844 countsByYear W20143368442015 @default.
• W2014336844 countsByYear W20143368442016 @default.
• W2014336844 countsByYear W20143368442019 @default.
• W2014336844 countsByYear W20143368442020 @default.
• W2014336844 countsByYear W20143368442021 @default.
• W2014336844 countsByYear W20143368442023 @default.
• W2014336844 crossrefType "journal-article" @default.

• next